The Fms-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase, is involved in the proliferation, differentiation and apoptosis of hematopoietic cells. FLT3 is highly overexpressed in acute myeloid leukemia (AML) of the majority of patients. Screening for flavonoids including flavones, flavanones, flavonols, and flavanonols disclosed that luteolin was potent FLT3 enzyme inhibitor. Furthermore, luteolin suppressed cell proliferation in MV4;11 cells with constitutively activated FLT3.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2013.01.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.
Int J Hematol
January 2025
Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.
View Article and Find Full Text PDFElectrochemical capacitance-based aptasensor for HER2 detection.
Biomed Microdevices
January 2025
Department of Physics, Faculty of Philosophy, Science and Letter, University of São Paulo, Ribeirão Preto, SP, 14040-901, Brazil.
The overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) protein is specifically related to tumor cell proliferation in breast cancers. Its presence in biological serum samples indicates presence or progression of cancer, becoming a promise biomarker. However, their detection needs a simple and high accuracy platform.
View Article and Find Full Text PDFReal-world 52-week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index.
J Dermatol
January 2025
Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long-term real-world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study aimed to evaluate 52-week real-world effectiveness of deucravacitinib in psoriasis patients, stratified by age (≥65 years vs <65 years) and BMI (≥25 vs <25).
View Article and Find Full Text PDFNovel PDGFRB Gene Fusions in Two Cases of Infantile Myofibromatosis.
Genes Chromosomes Cancer
January 2025
Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Infantile myofibromatosis (IM) comprises a wide clinical spectrum, ranging from solitary or multicentric lesions to generalized life-threatening forms. IM is mostly linked to germline or somatic heterozygous mutations in the PDGFRβ tyrosine kinase, encoded by the PDGFRB gene. Treatments for IM range from wait and see approach to systemic chemotherapy, according to the clinical context.
View Article and Find Full Text PDFThe emerging role of Bruton's tyrosine kinase inhibition in Urticaria Management.
Expert Opin Drug Saf
January 2025
Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Introduction: Bruton's tyrosine kinase (BTK) is a cytoplasmic signaling protein expressed across a variety of immune cells, terminally differentiated plasma cells, and natural killer cells. Due to the signal potential and targetable nature of BTK, the use of BTK inhibitors (BTKis) has been proposed for the management of several diseases. Currently, the use of BTKis is under investigations for several dermatological conditions such as pemphigus, systemic lupus erythematosus, hidradenitis suppurativa, atopic dermatitis, and chronic spontaneous urticaria (CSU).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!